A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease

Trial Profile

A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Apr 2018

At a glance

  • Drugs Clarithromycin/clofazimine/rifabutin (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms MAP-US; MAPUS
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 09 Apr 2018 According to a RedHill Biopharma media release, the last patient to reach the primary endpoint assessment (remission at week 26) is expected by early May 2018.
    • 22 Feb 2018 According to a RedHill Biopharma media release, top-line results from this trial are expected in mid-2018.
    • 16 Jan 2018 This trial has been completed in Bulgaria.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top